Biological Medicine for Diffuse Intrinsic Pontine Glioma (DIPG) Eradication
- Status
- UNKNOWN
- Phase
- PHASE2
Clinical Trials Related to Dasatinib
Related studies linked through entity extraction aliases.
Blinatumomab and Combination Chemotherapy or Dasatinib, Prednisone, and Blinatumomab in Treating Older Patients With Acute Lymphoblastic Leukemia
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE2
Explore the Synergy of Combination TKI Therapy
- Status
- WITHDRAWN
- Phase
- PHASE1
Study to Assess Dasatinib in Patients With Core Binding Factors Acute Myelogenous Leukemia
- Status
- COMPLETED
- Phase
- PHASE2
A Phase I Study of Oral Asciminib (ABL001) in Patients With CML or Ph+ ALL
- Status
- COMPLETED
- Phase
- PHASE1
Dasatinib in Treating Patients With Recurrent or Persistent Ovarian, Fallopian Tube, Endometrial or Peritoneal Cancer
- Status
- TERMINATED
- Phase
- PHASE2
Chemotherapy With Liposomal Cytarabine CNS Prophylaxis for Adult Acute Lymphoblastic Leukemia & Lymphoblastic Lymphoma
- Status
- TERMINATED
- Phase
- PHASE2
Selecting Patient-Specific Biologically Targeted Therapy for Pediatric Patients With Refractory Or Recurrent Brain Tumors
- Status
- UNKNOWN
- Phase
- NA
Randomized Phase III Study of Intensive Chemotherapy With or Without Dasatinib (Sprycelâ„¢)
- Status
- COMPLETED
- Phase
- PHASE3
A Phase 1B Study to Investigate the Safety and Preliminary Efficacy for the Combination of Dasatinib Plus Nivolumab in Patients With Chronic Myeloid Leukemia
- Status
- COMPLETED
- Phase
- PHASE1
Neoadjuvant Phase 2 Study Comparing the Effects of AR Inhibition With/Without SRC or MEK Inhibition in Prostate Cancer
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE2
OPTIM DASATINIB (Optimized Tyrosine Kinase Inhibitors Monotherapy)
- Status
- COMPLETED
- Phase
- PHASE2
Dasatinib for Patients Achieving Complete Molecular Response for Cure D-NewS Trial
- Status
- UNKNOWN
- Phase
- PHASE2
Dasatinib, Cytarabine, and Idarubicin in Treating Patients With High-Risk Acute Myeloid Leukemia
- Status
- TERMINATED
- Phase
- PHASE1/PHASE2
Dendritic Cell Vaccines + Dasatinib for Metastatic Melanoma
- Status
- COMPLETED
- Phase
- PHASE2
Combination of Dasatinib and Peg-Interferon Alpha 2b in First Line for Chronic Myeloid Leukemia in Chronic Phase
- Status
- COMPLETED
- Phase
- PHASE2
Open-Label Study Evaluating Dasatinib Therapy Discontinuation in Patients With Chronic Phase Chronic Myeloid Leukemia With Stable Complete Molecular Response
- Status
- COMPLETED
- Phase
- PHASE2
Study of Dasatinib, Androgen Deprivation Therapy and Radiation
- Status
- WITHDRAWN
- Phase
- PHASE1
De- Escalation and Stopping Treatment of Imatinib, Nilotinib or sprYcel in Chronic Myeloid Leukaemia
- Status
- COMPLETED
- Phase
- PHASE2
Dasatinib in Patients With Chronic Myeloid Leukemia in Chronic Phase
- Status
- UNKNOWN
- Phase
- PHASE2